Tower Research Capital LLC TRC Has $1.79 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Tower Research Capital LLC TRC lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 188.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,373 shares of the life sciences company’s stock after acquiring an additional 8,739 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Illumina were worth $1,787,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Golden State Wealth Management LLC bought a new position in Illumina during the fourth quarter worth $32,000. Versant Capital Management Inc grew its stake in Illumina by 153.7% during the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Illumina in the fourth quarter valued at approximately $45,000. Assetmark Inc. grew its position in shares of Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after buying an additional 296 shares during the period. Finally, Lee Danner & Bass Inc. acquired a new position in shares of Illumina during the 4th quarter valued at $48,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $74.35 on Wednesday. The firm has a market cap of $11.77 billion, a price-to-earnings ratio of -9.68, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The stock has a fifty day simple moving average of $83.43 and a two-hundred day simple moving average of $119.36. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ILMN. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. Guggenheim lowered their target price on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Stephens reissued an “overweight” rating and issued a $156.00 price target on shares of Illumina in a research report on Tuesday, March 11th. TD Cowen downgraded shares of Illumina from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Royal Bank of Canada reduced their price objective on shares of Illumina from $128.00 to $112.00 and set an “outperform” rating for the company in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Illumina presently has a consensus rating of “Moderate Buy” and a consensus price target of $138.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.